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Interindividual gene copy-number variation (CNV) of complement component C4 and its associated polymorphisms in
gene size (long and short) and protein isotypes (C4A and C4B) probably lead to different susceptibilities to autoimmune
disease. We investigated the C4 gene CNV in 1,241 European Americans, including patients with systemic lupus ery-
thematosus (SLE), their ﬁrst-degree relatives, and unrelated healthy subjects, by deﬁnitive genotyping and phenotyping
techniques. The gene copy number (GCN) varied from 2 to 6 for total C4, from 0 to 5 for C4A, and from 0 to 4 for C4B.
Four copies of total C4, two copies of C4A, and two copies of C4B were the most common GCN counts, but each
constituted only between one-half and three-quarters of the study populations. Long C4 genes were strongly correlated
with C4A ( ; ). Short C4 genes were correlated with C4B ( ; ). In comparison withRp 0.695 P ! .0001 Rp 0.437 P ! .0001
healthy subjects, patients with SLE clearly had the GCN of total C4 and C4A shifting to the lower side. The risk of SLE
disease susceptibility signiﬁcantly increased among subjects with only two copies of total C4 (patients 9.3%; unrelated
controls 1.5%; odds ratio [OR]p 6.514; ) but decreased in those with5 copies of C4 (patients 5.79%; controlsPp .00002
12%; ; ). Both zero copies ( ; ) and one copy ( ; ) of C4A wereORp 0.466 Pp .016 ORp 5.267 Pp .001 ORp 1.613 Pp .022
risk factors for SLE, whereas 3 copies of C4A appeared to be protective ( ; ). Family-based associationORp 0.574 Pp .012
tests suggested that a speciﬁc haplotype with a single short C4B in tight linkage disequilibrium with the 5308A allele
of TNFA was more likely to be transmitted to patients with SLE. This work demonstrates how gene CNV and its related
polymorphisms are associated with the susceptibility to a human complex disease.
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Systemic lupus erythematosus (SLE [MIM 152700]) is a
complex, prototypic autoimmune disease that predomi-
nantly affects women of child-bearing age. The hallmark
of SLE is the generation of autoantibodies that react with
self nuclear and cytoplasmic antigens, culminating in im-
munologic attacks to body organs.1–3 Although under in-
tense investigations, the genetic basis of human SLE is still
not well understood.4–6
Complement component C4 (with isotopes C4A [MIM
120810] and C4B [MIM 120820]) is an effector protein of
the immune system. It plays a pivotal role in the activation
of the classical and the lectin complement pathways that
lead to cytolysis or neutralization of invading microbes,
opsonization of targets for phagocytosis, clearance of
immune complexes, disposal of apoptotic materials, and
reduction of the threshold for activation of B lympho-
cytes.7–11 The link between the total deﬁciency of com-
plement component C4 and human SLE was ﬁrst ob-
served in 1974.12 It is known that complete or homozy-
gous deﬁciency in any of the early components for the
classical activation pathway of the complement system,
such as C1q (MIM 120550, 120570, and 120575), C1r
(MIM 216950), C1s (MIM 120580), and C4, are among the
strongest genetic risk factors associated with human SLE.
More than 75% of human subjects completely deﬁcient
in C1 or C4 proteins have SLE or lupus-like disease.13,14
Animal studies conﬁrmed that homozygous deﬁciencies
of C1q or C4 in mice can be causative genetic factors for
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SLE.15–18 However, the prevalence of complete deﬁciency
of C4 or subunit proteins of the C1 complex in humans
is extremely rare: only 84 cases have been reported so
far.11,14,19,20 Much more common is the low plasma or se-
rum protein levels of these complement proteins, partic-
ularly C4 or one of its isotypes, C4A.21,22 These abnor-
malities are present in 30%–40% of patients with SLE.20,23
Curiously, in many healthy subjects, the low range of C4
plasma protein concentrations overlaps that of patients
with SLE. The complex genetics of human C4 has pre-
cluded a simple interpretation of the mechanism for low
C4 protein levels in health and SLE.
The polymorphic C4 proteins are categorized into two
isotypes, C4A and C4B, each with multiple allotypes.10,24,25
The C4A and C4B proteins exhibit marked differences in
chemical reactivities to substrates, although they share
199% amino acid sequence identity. The isotype-speciﬁc
residues are encoded by exon 26 and are located at amino
acid residues 1101–1106, which are PCPVLD for C4A and
LSPVIH for C4B (differences underlined).26–28 The thioester
bond present in the activated C4A has a longer half-life
against hydrolysis (∼10 s) than that of C4B (!1 s). The
thioester carbonyl group of C4A effectively forms a co-
valent amide bond with amino group–containing sub-
strates, such as protein antigens. The activated C4B is
highly reactive because one of its isotypic residues, His
1106, catalyzes a nucleophilic attack of the thioester car-
bonyl group on hydroxyl group–containing substrates to
form a covalent ester linkage.29–32 Therefore, it is thought
that C4A proteins are more important in immunoclear-
ance and that C4B proteins are more relevant in the de-
fense against microbes.
The impetus for the present study is that our earlierwork
in healthy European Americans revealed an interindivi-
dual variation in the C4 gene copy number (GCN) and
dichotomies of C4 gene size and C4 protein isotypes.33–38
In the central region of the human major histocompati-
bility complex (MHC) on each chromosome 6 (ﬁg. 1),
there can be 1, 2, 3, or 4 copies of C4 genes. Theoretically,
two to eight copies of C4 genes can be present in a diploid
genome of a given individual. The C4 gene size has two
forms, long and short. The long gene is 21 kb in length,
and the short gene is 14.6 kb. The long gene is due to the
integration of the endogenous retrovirus HERV-K(C4) into
its ninth intron.10,37,42 Our earlier analysis revealed that,
among subjects with equal copy numbers of C4 genes,
subjects with short genes have C4 plasma protein levels
relatively higher than those of subjects with long genes.43
Irrespective of gene size, each C4 gene can code for either
an acidic C4A protein or a basic C4B protein.
The duplication or multiplication of C4 genes is dis-
cretely modular. The breakpoint(s) of duplication are iden-
tical among duplicatedmodules.33,34 Each duplicatedmod-
ule also includes three genes neighboring C4. In MHC
haplotypes with a single C4 gene, there are single and
intact genes coding for the nuclear protein kinase RP1
(RP1, also known as “STK19” [MIM 604977]) at the 5′ re-
gion, the steroid cytochrome P450 21-hydroxylase
(CYP21B, also known as “CYP21A1” [MIM 201910]), and
the extracellular matrix protein tenascin-X (TNXB [MIM
600985]) at the 3′ region of C4. In MHC haplotypes with
two or more C4 genes, concurrently present with each
duplicated C4 gene are a complete sequence for CYP21
and partial sequences for TNX (i.e., TNXA) and RP (i.e.,
RP2). The duplicated C4 genes are usually functional, and
they can code for either a C4A protein or a C4B protein.
The additional CYP21 gene can be a nonfunctional
CYP21A (also known as CYP21A1P) with multiple se-
quence alterations, including three deleterious nonsense
mutations, or a functional CYP21B gene (see GenBank
for entries of sequences of speciﬁc genes).33,34,44–46 This
phenomenon is referred to as the “RCCX modular
duplication.”34,35
To investigate the complex genetic diversity of comple-
ment C4, we genotyped the RCCX modules and deter-
mined the gene copy-number variation (CNV) of totalC4,
C4A, C4B, and the long and short C4 genes in patients
with SLE, their ﬁrst-degree relatives, and unrelatedhealthy
controls. The genotype data were independently con-
ﬁrmed by phenotyping experiments that elucidated the
C4A and C4B protein polymorphisms in EDTA plasma
(i.e., plasma collected in EDTA). Our primary goal was to
determine whether totalC4 (i.e.,C4A plusC4B),C4A, and/
or C4B CNVs are genetic risk factors for SLE. The results
provide concrete data of gene CNV for an important im-
mune-defense protein in health and disease, suggesting
that low copy number is a risk factor for and high copy
number is a protective factor against susceptibility to hu-
man SLE.
Material and Methods
Study Populations
The protocols for human subject recruitment and study were ap-
proved by institutional review boards of the Ohio State Univer-
sity, the Columbus Children’s Hospital, and the University of
California–Los Angeles. To avoid confounding factors affecting
C4 genetics among different racial and/or ethnic groups, the cur-
rent report focuses primarily on patients with SLE who are Amer-
icans of European ancestry ( ), their ﬁrst-degree relativesnp 233
( ), and unrelated healthy European Americans (np 362 np
) residing in central Ohio. The patients all satisﬁed four or517
more diagnostic criteria for SLE from the American College of
Rheumatology.47 The mean age (SD) of the female patients with
SLE ( ), female ﬁrst-degree relatives ( ), male pa-np 216 np 221
tients with SLE ( ), and male ﬁrst-degree relatives (np 17 np
) was years, years, years,142 41.2 14.9 57.7 14.9 38.2 15.4
and years, respectively. The mean age of unrelated,58.0 15.6
healthy, European American female ( ) and male (np 389 np
) controls was 38.6  11.1 years and 34.3  12.1 years, re-128
spectively (table 1).
An independent replication study was performed using 128
patients with SLE: 99 European American patients (89 females
with mean age years; 10 males with mean age37.4 11.6
years) from Los Angeles and 29 female patients with40.9 13.0
white European ancestry (mean age years) from the46.6 13.0
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Figure 1. CNVs and size variations of complement C4 genes and RCCX modules in the human MHC. A, Map showing the gene organization
of the MHC-complement gene cluster with a bimodular LL haplotype for RCCX. Horizontal arrows represent gene transcriptional orien-
tations. The PmeI restriction sites ﬂanking the RCCX modules in BF and TNXB are shown as dotted arrows. Vertical arrows with letters
depict the locations and names of DNA probes employed for genomic Southern-blot analyses. B, Structures and conﬁgurations of RCCX
length variants observed in the white study populations. The fragment sizes of TaqI restriction fragments for RP-C4, CYP21, and TNX
are shown on the right.39–41
Antiphospholipid Syndrome Registry Collaborative Registry (AP-
SCORE). The APSCORE patients had SLE and antiphospholipid
antibodies but did not receive a diagnosis of deﬁnite or expanded
antiphospholipid syndrome. The clinical characteristics of the
patients with SLE who are from Ohio and California are sum-
marized in table 2.
Processing of Blood Samples
EDTA plasma was harvested by centrifugation and was stored at
86C. Peripheral blood leukocytes were prepared via Ficoll gra-
dient centrifugation for preparation of DNA plugs in low-gelling-
temperature agarose and were used for long-range mapping ex-
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Table 1. Demographic Data of Ohio SLE Cohort
Group
No. of
Subjects
Agea
(years) BMIa
Female patients with SLE 216 41.2  14.9 29.0  7.4
First-degree relatives:
Female 221 57.7  14.9 29.6  8.4
Male 142 58.0  15.6 29.2  5.7
Male patients with SLE 17 38.2  15.4 29.1  6.6
NOTE.—Cohort also included 517 unrelated, healthy European American
controls (389 females and 128 males).
a Data are mean  SD.
Table 2. Clinical Features of Patients with SLE Related
to American College of Rheumatology Criteria for Diagnosis
of SLE
Diagnostic Criterion
Frequency of Criterion
(%)
Ohio SLE Study
( )anp 233
California SLE Study
( )bnp 99
Malar rash 50.9 59.6
Discoid rash 7.63 14.3
Photosensitivity 32.2 81.4
Oral ulcer 31.4 42.2
Arthritis 83.1 94.9
Serositis 31.4 55.2
Renal disorder 36.4 31.6
Neurologic disorder 12.7 12.4
Hematologic disorder: 37.3 53.8
Hemolytic anemia 8.05 10.4
Leukopenia 13.6 38.2
Lymphopenia 9.75 30.3
Thrombocytopenia 14.0 18.1
Immunologic disorder: 43.2 74.0
Anti-DNA 43.6 61.1
Anti-Sm 6.78 9.72
Antinuclear antibody 91.1 100
a Included 17 males and 216 females (males:females 1:12.7).
b Included 10 males and 89 females (males:females 1:8.9).
periments involving pulsed-ﬁeld gel electrophoresis (PFGE).
Genomic DNA samples for RFLP analyses were prepared from
whole blood by use of Puregene kits (Gentra Systems).39
Determination of GCN and Gene Size of C4A, C4B,
and RCCX Modular Variations
Elsewhere, we have described detailed procedures for genotyping
and phenotyping of complement C4.40,41 TaqI genomic RFLP was
performed employing speciﬁc probes A, E, and F (ﬁg. 1A), cor-
responding to the genomic regions containing RP, C4, CYP21,
and TNX. Results of the TaqI Southern blots yielded information
on the GCN and gene size of C4 and the copy numbers of three
other constituent genes in the RP-C4-CYP21-TNX (RCCX) mod-
ules in the central region of the MHC on chromosome 6p21.3.
The relative GCN of C4A and C4B were determined by PshAI-
PvuII genomic RFLP that distinguished the C4A and C4B isotypic
sites.
Determination of RCCX Haplotype and Number and Size
of C4 Genes on Each Chromosome 6 by PFGE
of PmeI-Digested DNA
To conﬁrm further the presence of quadrimodular, trimodular,
bimodular, and monomodular RCCX structures present in each
individual, human genomic DNA trapped in agarose plugs (to
avoid shearing and mechanical breakage) was digested with the
rare-cutter restriction enzyme PmeI, was subjected to PFGE, and
then underwent Southern-blot analysis. The RCCX modular
structures were represented as PmeI restriction fragments of the
following sizes: monomodular short (S), 107 kb; monomodular
long (L), 113 kb; bimodular short-short (SS), 133 kb; bimodular
long-short (LS), 139 kb; bimodular long-long (LL), 146 kb; tri-
modular long-short-short (LSS), 165 kb; trimodular long-short-
long (LSL) or long-long-short (LLS), 172 kb; trimodular long-long-
long (LLL), 179 kb; quadrimodular long-short-short-short (LSSS),
192 kb; and quadrimodular long-long-long-long (LLLL), 211 kb.41
Determination of C4A and C4B Allotypes and Plasma
Protein Concentrations
EDTA plasma samples were digested with neuraminidase and car-
boxyl peptidase B, followed by (nonreducing) high-voltage aga-
rose-gel electrophoresis.48,49 Complement C4A and C4B allotypes
were revealed by immunoﬁxation by use of goat anti-human C4
antibody and staining with Simple Blue dye (Invitrogen). Protein
band intensities for C4A and C4B allotypes were quantiﬁed by
ImageQuant software (Amersham). Plasma protein levels of total
C4 were determined by single radial immunodiffusion (The Bind-
ing Site). C4A and C4B protein concentrations were calculated
from their relative quantities revealed by immunoﬁxation
experiments.
Statistical Analyses
x2 analyses were performed to determine the differences in total
C4, C4A, and C4B gene CNV among various groups. One-way
analysis of variance (ANOVA) was used to compare the gene-copy
indices of total C4, C4A, C4B, and long and short C4 across three
or more groups; analysis was adjusted for dependence based on
data for families with SLE, and Tukey “Honestly Signiﬁcantly Dif-
ferent” test, performed at the 0.05 signiﬁcance level, was used to
distinguish different clusters of groups. Two-group comparisons
for these data were based on post hoc two-sample Student’s t
tests. Odds ratios (ORs) and 95% CIs were calculated by analysis
of tables, and Fisher’s exact test was used for comparison.2# 2
Statistical analyses were performed on SAS JMP version 6 (SAS
Institute) and SPSS version 11.5 (SPSS) software. Transmission/
disequilibrium tests of complement C4A, C4B, and RCCX hap-
lotypes in families with SLE were performed using the computer
program FBAT.50
Results
Genetic Mechanisms Leading to Lower Expression of C4A
Protein Than of C4B Protein in Families with SLE
The prospective SLE study population consisted entirely
of European Americans residing in Ohio. There were 233
patients with SLE, 362 ﬁrst-degree relatives (parents and
siblings) of the patients with SLE, and 517 unrelated
healthy controls. The RCCX modular structures and the
copy number of long and short C4 genes were elucidated
by Southern-blot analyses of PmeI-digested genomic DNA
resolved by PFGE and by TaqI genomic RFLP (ﬁg. 1A). The
relative GCN of C4A and C4B were determined by ge-
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Figure 2. Different genetic mechanisms leading to lower expression of C4A protein than of C4B protein in four families with SLE. In
each family, the RCCX modular structures were determined by PFGE of PmeI-digested genomic DNA, Southern blotting, and hybridization
to a C4d-speciﬁc probe (A). TaqI genomic RFLP was applied to yield details of genomic structures for the RCCX constituents, including
the dichotomies of RP1 and RP2, C4 long and C4 short linked to RP1 or RP2, CYP21B, CYP21A, TNXB, and TNXA (B). PshAI-PvuII RFLP
was applied to determine the relative GCNs of C4A and C4B (C). The C4A and C4B protein polymorphisms were elucidated by immunoﬁxation
of EDTA plasma resolved by high-voltage agarose-gel electrophoresis (D). P p patient; M p mother; F p father; S p sibling (S1 p
sibling 1; S2 p sibling 2).
nomic PvuII-PshAI RFLP that distinguished C4A and
C4B isotypic sequences. The C4A and C4B protein poly-
morphisms were determined by immunoﬁxation of
EDTA plasma resolved by high-voltage agarose-gel
electrophoresis.
In ﬁgure 2 and table 3, we present four examples by
which the patient with SLE had a C4A plasma protein level
lower than that of C4B, a general phenomenon observed
inmany European American patients with SLE. The results
reveal that, if a subject is heterozygous and one of the
RCCX haplotypes is bimodular (containing one C4A gene
and one C4B gene), four different scenarios exist for the
other haplotype that can lead to a lower effective GCN of
C4A than of C4B: (a) monomodular S RCCX with a single,
short C4B gene (families 4 and 183), (b) monomodular L
RCCX with a single, long C4B gene (family 20), (c) bi-
modular RCCXhaplotype that contains amutantC4A and
a functional C4B (family 183), and (d) multimodular
RCCX haplotype with higher GCN for C4B than for C4A
(family 109). Detailed results on the CNVs of total C4,
C4A, C4B, long C4, short C4, and RCCX modules in all
study subjects are summarized in table 4.
C4 GCN in Female European American Patients with SLE,
Female First-Degree Relatives, and Unrelated Healthy Female
Controls
Because our patients with SLE are predominantly female
(females:males 12.7:1), our primary analyses were focused
on female subjects.51–53 We ﬁrst examined the CNV for
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Table 3. Summary of RCCX Modules, Gene CNV, and Protein Polymorphisms of Total C4, C4A, and C4B in Four Selected
Families with SLE
Family
and Subject RCCX-1 RCCX-2
GCN Allotypes
Concentrationa
(mg/dl)
C4A
MutationbC4 C4A C4B C4A C4B Total C4 C4A C4B
4:
Patient LL S 3 1 2 A3 B1, B1 20.8 5.0 15.6 No
Mother LL LL 4 2 2 A3, A3 B1, B2 51.3 25.3 28.1 No
Father LL S 3 1 2 A3 B1, B1 36.0 16.6 19.4 No
Sibling LL LL 4 2 2 A3, A3 B1, B1 25.4 12.6 12.8 No
20:
Patient LL L 3 1 2 A3 B1, B1 15.0 4.9 10.0 No
Mother LS L 3 1 2 A3 B1, B1 23.6 10.7 12.8 No
Sibling LL LS 4 2 2 A3, A3 B1, B1 38.9 18.6 20.3 No
183:
Patient LS S 3 1 2 AQ0 B1, B2 22.5 0 22.5 Yes
Mother LLL LS 5 3 2 A3, A3, AQ0 B1, B2 34.3 17.1 17.3 Yes
Sibling LLL S 4 2 2 A3, A3 B1, B1 33.5 13.7 19.8 No
109:
Patient LSSS LL 6 2 4 A3, A3 B1, B1, B1, B1 41.4 11.8 29.6 No
Mother LL LL 4 2 2 A3, A3 B1, B1 33.6 16.9 16.7 No
Sibling 1 LL LS 4 2 2 A3, A3 B1, B2 40.8 19.0 21.7 No
Sibling 2 LSSS LL 6 2 4 A3, A3 B1, B1, B1, B1 68.6 22.6 43.0 No
a Plasma protein concentrations.
b 2-bp insertion at codon 1213 in exon 29 of C4A (C4AQ0, mutant C4A without a protein product).
total C4 genes. In the unrelated female controls (np
), the variation of C4 GCN showed a pattern close to389
normal distribution. The majority (59.4%) had four copies
of C4 genes. The frequencies of subjects with two, three,
ﬁve, and six copies of C4 genes were 1.5%, 27.0%, 10.5%,
and 1.5%, respectively (table 4 and ﬁg. 3A).
In female European American patients with SLE (np
), a shift of the C4 GCN distribution to the low216
gene-dosage side was observed ( ; ;2x p 27.5 dfp 4 Pp
). Slightly more than half the patients (51.9%) had.000016
four copies of C4 genes. The frequency of subjects with
two and three copies of C4 genes increased to 9.3% and
32.9%, respectively. By contrast, the frequencies of sub-
jects with ﬁve and six C4 genes decreased to 5.1% and
0.9%, respectively. In comparison with female controls,
the OR of patients with SLE who have only two copies of
C4 genes is 6.51 (95% CI 2.57–16.5; ); the ORPp .00002
of patients with SLE with ﬁve or six copies of C4 genes is
0.466 (95% CI 0.25–0.88; ) (ﬁg. 3D).Pp .016
We deﬁne gene-copy index as the mean copy number
of a gene that manifests interindividual gene CNV in a
selected population. The gene-copy index of C4 was high-
est in the unrelated controls (3.81), lowest in the female
patients (3.56; for FP vs. FC), and intermediateP ! .0001
in the female ﬁrst-degree relatives (3.67; for FFPp .036
vs. FC).
Low C4A GCN in Female European Americans with SLE
The reduction of C4 GCN in patients with SLE can be the
result of a decrease in C4A, C4B, or both. Therefore, we
examined the distribution patterns of C4A and C4B
among the female patients, ﬁrst-degree relatives, and un-
related controls (ﬁgs. 3B and 3C).
Total absence of C4A genes (homozygous C4A deﬁ-
ciency) had a frequency of 6.5% in female patients with
SLE, compared with 1.3% in unrelated controls (ORp
; 95% CI 1.87–14.8; ). Of the patients, 26%5.27 Pp .001
had only one copy of the C4A gene (i.e., heterozygous
C4A deﬁciency), compared with 18.2% of unrelated con-
trols ( ; 95% CI 1.1–2.4; ). Conversely,ORp 1.61 Pp .022
high C4A GCN (i.e., three, four, or ﬁve copies of C4A
genes) was observed in 15.3% of the patient group, com-
pared with 23.8% of the control group ( ; 95%ORp 0.57
CI 0.37–0.89; ). Overall, the pattern of C4A GCNPp .012
distribution in female patients with SLE was signiﬁcantly
different from that in unrelated healthy controls ( 2x p
; ; ). Similar to total C4, the distri-25.1 dfp 5 Pp .00014
bution pattern of C4A GCN for the female ﬁrst-degree
relatives was also between the patterns for patients with
SLE and unrelated controls (ﬁg. 3B).
The gene-copy index of C4A among female unrelated
controls, ﬁrst-degree relatives, and patients with SLE was
2.05, 1.92 ( for FF vs. FC), and 1.81 ( forPp .05 Pp .0005
FP vs. FC), respectively (table 5).
Unlike C4A, no signiﬁcant differences in C4B GCN dis-
tribution patterns were observed among female patients,
their ﬁrst-degree relatives, and unrelated controls. Among
the patients with SLE, 70.8% had the medium C4B gene
dosage, with two copies of C4B genes (ﬁg. 3C). The C4B
gene-copy index in all three groups was similar (range
1.74–1.77) (table 3). Therefore, the main cause for the low
GCN of total C4 in European American patients with SLE
was the low GCN of C4A.
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Table 4. CNV of C4 and RCCX Modules among European American Female and Male Controls (FC and MC, respectively),
Female and Male First-Degree Relatives (FF and MF, respectively), Female Patients with SLE from Ohio Study (FP),
and Female Patients with SLE from a Replication Study (SP)
Genes or
Haplotypes
and Group
FC MC FF MF FP SP
No. Frequency No. Frequency No. Frequency No. Frequency No. Frequency No. Frequency
Total C4 genes:
2 6 .015 1 .008 14 .063 10 .07 20 .093 3 .025
3 105 .27 30 .234 68 .308 48 .338 71 .329 45 .381
4 231 .594 81 .633 120 .543 71 .5 112 .519 62 .525
5 41 .105 12 .094 15 .068 13 .092 11 .051 4 .034
6 6 .015 4 .031 4 .018 0 0 2 .009 4 .033
Total 389 … 128 … 221 … 142 … 216 … 118 …
C4A genes:
0 5 .013 0 0 6 .027 6 .043 14 .065 3 .025
1 70 .182 19 .148 53 .241 37 .262 57 .264 39 .331
2 218 .566 71 .555 121 .55 77 .546 112 .519 63 .534
3 81 .21 30 .234 32 .145 20 .142 24 .111 11 .093
4 9 .023 8 .063 8 .036 1 .007 8 .037 1 .008
5 2 .005 0 0 0 0 0 0 1 .005 1 .008
Total 385 … 128 … 220 … 141 … 216 … 118 …
C4B genes:
0 9 .023 5 .039 5 .023 5 .035 6 .028 3 .025
1 99 .257 39 .305 52 .236 27 .191 49 .227 16 .136
2 250 .649 75 .586 158 .718 102 .723 153 .708 90 .763
3 26 .068 9 .07 4 .018 7 .05 7 .032 6 .051
4 1 .003 0 0 1 .005 0 0 1 .005 3 .025
Total 385 … 128 … 220 … 141 … 216 … 118 …
Long C4 genes:
0 4 .01 0 0 5 .023 3 .021 10 .046 0 0
1 26 .067 5 .039 18 .082 18 .127 20 .093 9 .101
2 100 .257 29 .227 60 .273 37 .261 63 .292 30 .337
3 145 .373 46 .359 78 .355 58 .408 68 .315 30 .337
4 98 .252 44 .344 53 .241 22 .155 51 .236 17 .191
5 14 .036 3 .023 5 .023 4 .028 3 .014 2 .022
6 2 .005 1 .008 1 .005 0 0 1 .005 1 .011
Total 389 … 128 … 220 … 142 … 216 … 89a …
Short C4 genes:
0 130 .334 51 .398 64 .291 35 .246 70 .324 20 .225
1 170 .437 59 .461 109 .495 69 .486 96 .444 47 .528
2 80 .206 11 .086 42 .191 36 .254 43 .199 19 .213
3 8 .021 7 .055 4 .018 2 .014 6 .028 1 .011
4 1 .003 0 0 1 .005 0 0 1 .005 2 .022
Total 389 … 128 … 220 … 142 … 216 … 89a …
RCCX haplotypes:
L 33 .042 14 .055 31 .07 21 .074 32 .074 5 .028
S 88 .113 20 .078 55 .125 43 .151 73 .169 28 .157
LL 387 .497 139 .543 205 .466 117 .412 199 .461 76 .427
LS 208 .267 60 .234 123 .28 85 .299 105 .243 54 .303
SS 1 .001 0 0 1 .002 1 .004 4 .009 0 0
LSL 11 .014 3 .012 7 .016 5 .018 6 .014 2 .011
LSS 25 .032 8 .031 7 .016 6 .021 5 .012 6 .034
LLL 24 .031 11 .043 10 .023 6 .021 7 .016 6 .034
SSS 0 0 1 .004 0 0 0 0 0 0 0 0
LSSS 0 0 0 0 1 .002 0 0 1 .002 0 0
LLLL 1 .001 0 0 0 0 0 0 0 0 1 .006
Total 778 … 256 … 440 … 284 … 432 … 178a …
a Copy numbers of long C4, short C4, and RCCX haplotypes in SP were calculated from California SLE cohort.
CNV of Long and Short C4 Genes and Their Correlations
with C4A and C4B
We then examined the variations of long and short C4
genes. In all three groups of female subjects, the copy
number of long genes varied from 0 to 6, whereas that of
short genes varied from 0 to 4. Three copies of long C4
genes and one copy of a short C4 gene were the most
prevalent counts among all study groups (ﬁgs. 4A and 4B).
The gene-copy index of long C4 was 2.66 in patients with
SLE and 2.91 in unrelated controls ( , by Student’sPp .006
t test) (table 5). No signiﬁcant difference was observed for
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Figure 3. C4 gene CNVs in female patients with SLE, ﬁrst-degree relatives, and unrelated healthy subjects. A–C, Distribution patterns
of total C4, C4A and C4B GCN groups among white female patients with SLE (FP [red bars]), their female ﬁrst-degree relatives (FF [yellow
bars]), and unrelated female controls (FC [blue bars]). D and E, GCN-dependent variation in OR and SLE disease susceptibility for total
C4 (D) and C4A (E).
the gene-copy index of short C4, which was 0.94 in pa-
tients with SLE and 0.93 in unrelated female controls.
The next question we asked was about the degree of
correlation between long or short C4 genes and C4A or
C4B (table 6). Among three female population groups, the
Pearson’s coefﬁcients of correlation (R) between long C4
genes and C4A were 0.77, 0.69, and 0.64 for patients with
SLE, female ﬁrst-degree relatives, and unrelated female
controls, respectively. The overall correlation coefﬁcient
between long genes and C4A was 0.70 ( ). TheP ! .0001
Pearson’s coefﬁcient of correlation between shortC4 genes
and C4B was 0.48, 0.38, and 0.44 for the patients with
SLE, female ﬁrst-degree relatives, and female unrelated
controls, respectively. The overall coefﬁcient of correlation
between short genes and C4B was 0.44 ( ).P ! .0001
Inverse correlations between long genes and C4B and
between short genes and C4A were observed in most
groups. Such inverse correlations implied that the greater
the copy number of long C4 genes in an individual, the
less likely there will be an increase in copy number of
C4B, and the greater the number of short C4 genes, the
less likely there will be an increase in the copy number
of C4A.
Increase in Monomodular RCCX and Decrease in Bimodular
and Trimodular RCCX in SLE
The PmeI-PFGE and the TaqI genomic RFLP data allowed
us to examine the constituents of the RCCX haplotypes
and the conﬁgurations of long and short C4 genes in the
RCCX. Seven common (L, S, LL, LS, LSL, LSS, and LLL;
frequency for each haplotype 11%) and four rare (SS, SSS,
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Table 5. Comparison of Gene-Copy Indices for Total C4, C4A, C4B, Long C4, and Short
C4 among Patients with SLE, Their First-Degree Relatives, and Unrelated Healthy
Controls
Cohort and Group
or Variable n
Gene-Copy Index  SD
Total C4 C4A C4B Long C4 Short C4
Ohio SLE Cohort:
FC 389 3.81  .75 2.05  .79 1.77  .61 2.91  1.03 .93  .80
FF 221 3.67  .77 1.92  .80 1.74  .55 2.80  1.07 .93  .75
FP 216 3.56  .77 1.81  .89 1.76  .58 2.66  1.14 .94  .82
MC 128 3.83  .83 2.21  .77 1.65  .68 3.11  .94 .80  .82
MF 141 3.62  .75 1.81  .76 1.79  .58 2.63  1.05 1.04  .75
MP 17 3.53  .72 1.71  .77 1.82  .53 2.53  1.07 1.00  .87
P value:
FP vs. FC … .0001 .0005 … .005 …
FF vs. FC … .036 .05 … NS …
MP vs. MC … NS .015 … .033 …
MF vs. MC … .05 .0002 … .001 …
MC vs. FC … NS .045 … NS …
Overall … .002 .0001 NS .002 NS
Replication cohort:
SP 118 3.68  .77 1.75  .76 1.92  .66 2.73  1.03 1.08  .83
P value:
SP vs. FC … NS .0007 .015 NS NS
SP vs. FP … NS NS .019 .04 .009
Overalla … .0003 .0001 .035 .001 .04
NOTE.—Gene-copy index is the mean copy number of a speciﬁc gene in a selected population. FC p
female unrelated controls; FF p ﬁrst-degree female relatives of patients with SLE; FPp female patients
with SLE; MC p male unrelated controls; MF p ﬁrst-degree male relatives of patients with SLE; MP p
male patients with SLE; NS p not signiﬁcant; SP p female patients with SLE in the replication study.
a The overall P value was determined by the ANOVA F test after dependence adjustment. Student’s
post hoc t test was used to calculate P values for each individual pair.
LSSS, and LLLL; frequency for each haplotype !1%) RCCX
length variants were detected (ﬁg. 1B and table 4).
The frequencies of monomodular haplotypes with a sin-
gle short C4 gene or a single long C4 gene was 15.5% in
unrelated female controls and 24.3% in female patients
with SLE ( ; ). By contrast, the fre-2x p 14.0 Pp .0002
quency with trimodular/quadrimodular RCCXhaplotypes
was 7.8% in the unrelated control group compared with
4.4% in the patient group ( ; ). Overall,2x p 5.33 Pp .02
the distributions of RCCX haplotypes between patients
with SLE and unrelated controls were signiﬁcantly differ-
ent ( ; ), but those between female ﬁrst-2x p 15.9 Pp .0032
degree relatives and unrelated controls were not ( 2x p
; ) (ﬁg. 4C).6.92 Pp .14
Bimodular LL and bimodular LS were themost common
RCCX haplotypes among all European American subjects.
A modest difference in the frequency of bimodular struc-
tures between patients with SLE (70.4%) and controls
(76.5%) was observed ( ; ).2x p 5.43 Pp .02
Association of TNFA 308GrA Polymorphism with SLE,
Secondary to the Monomodular S RCCX Haplotypes
with Absence of C4A
The 308A allele (also known as “TNF2”) of the human
tumor necrosis factor-a gene (TNFA) has been suggested
to be associated with autoimmune diseases, including
SLE.54–56 Because TNFA is located 403.5 kb telomeric to
complement C4 in the MHC class III region, we compared
the frequencies of TNF2 among female European Ameri-
can patients with SLE, their female ﬁrst-degree relatives,
and healthy female controls. Overall, the allelic frequency
of TNF2 was 0.17 in unrelated healthy controls and 0.231
in the patients with SLE ( ; ; ).2x p 4.5 Pp .039 ORp 1.48
The roles of TNF2 and low C4A GCN as risk factors of
SLE are compared by two methods. First, we categorized
the study subjects according their C4A GCN—low (GCN
of zero or one), medium (GCN of two), or high (GCN of
three, four, ﬁve, or six)—and then compared the fre-
quency of TNF1 and TNF2 in each group. Second, we seg-
regated the study subjects into TNF1 (308GG) and TNF2
(308GA or 308AA) carriers and then compared the fre-
quencies of low, medium, and high C4A GCN in each
group (table 7). When the C4A GCN groups were con-
trolled for, there was no consistent increase in the fre-
quency of TNF2 in the patients with SLE. No signiﬁcant
difference was observed for the distribution of the TNF1-
and TNF2-carrier frequencies between the healthy con-
trols and the patients with SLE among the subjects with
low, medium, or high C4A GCN. When TNF1 and TNF2
carriage was controlled for, there was a consistent increase
in the frequencies of low C4A GCN and a consistent de-
crease in the frequencies of high C4A GCN in the patients
with SLE, compared with controls. In particular, a great
difference in frequencies of low C4A GCN was observed
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Figure 4. Distribution patterns of long and short C4 genes and
RCCX haplotype structures among female patients with SLE (FP [red
bars]), their female ﬁrst-degree relatives (FF [yellow bars]), and
unrelated female controls (FC [blue bars]). A, Gene CNV of long
C4. B, Gene CNV of short C4. C, Haplotype variation of RCCX struc-
tures. T-Q p trimodular and quadrimodular.
between the control group (39.6%) and the patients with
SLE (70.1%) among the subjects who are TNF2 carriers
( ; ), suggesting that low C4A GCN is a2x p 16.0 Pp .0003
strong risk factor for SLE among the subjects who areTNF2
carriers. Of equal importance is the substantial reduction
in the frequency of subjects with high C4A GCN (8.05%)
in patients with SLE, compared with healthy controls
(30.2%). These analyses suggest that C4A gene CNV is
likely a more important risk factor for human SLE than is
the TNFA 308GrA polymorphism.
Among the TNF2 alleles in the unrelated control group,
slightly less than half were linked to the monomodular S
haplotype of RCCX with the presence of a single short
C4B gene (i.e., with the absence of a C4A gene). This hap-
lotype is abbreviated as S-TNF2. A segregation analysis of
TNF2 haplotypes in the S-TNF2 group and the nonS-TNF2
group revealed two relevant features (ﬁg. 5). First, the fre-
quency of the S-TNF2 group in the patients with SLE was
2.1 times greater than that in the healthy controls (pa-
tients with SLE 0.164; controls 0.079). Second, the fre-
quency of the nonS-TNF2 group in the patients with SLE
was less than that in the healthy controls (patients 0.067;
controls 0.091) ( ; ). This observation fur-2x p 13.7 Pp .003
ther underscores the importance of complement C4A de-
ﬁciency as a primary genetic risk factor in the MHC class
III region associated with SLE.
Family-Based Association Test (FBAT) Reveals Monomodular
S RCCX C4B with C4A Deﬁciency and TNFA Promoter
Polymorphism as Risk Factors and C4A6 as a Protective
Factor for SLE
FBAT was applied, to analyze whether haplotypes with
speciﬁc RCCX length variants, C4A and C4B protein al-
lotypes, and TNFA promoter polymorphisms are genetic
risk factors for SLE. It is anticipated that a SLE risk factor
would be transmitted more frequently from parents to
offspring who develop SLE. The analytical technique FBAT
works robustly against the bias caused by genetic admix-
ture and stratiﬁcation.50
As shown in table 8, the monomodular RCCX structures
with either a long or short C4 gene had a higher-than-
expected frequency of transmission to the patient popu-
lation, with a P value of .014. Further analysis demon-
strates a highly signiﬁcant increase in the transmission of
the monomodular S haplotype to the patient ( ).Pp .005
There were 46 different combinations of C4A and C4B
protein allotypes in the Ohio SLE families. Among them,
12 haplotypes each had a frequency 11%. C4 protein hap-
lotypes without a C4A protein (i.e., C4B1, C4AQ0-B1, and
C4AQ0-B2) were more frequently transmitted to patients
( ), supporting a probable role of C4A deﬁciencyPp .013
as a risk factor for SLE development. In addition, the hap-
lotype with C4A6-B1 was less frequently transmitted to
patients ( ), suggesting a possible protective role ofPp .03
C4A6 against SLE disease susceptibility.
We further analyzed the transmission of speciﬁc RCCX
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Table 6. Pearson Coefﬁcient of Correlation (R) of Long and Short C4 Genes
with C4A and C4B in Female Patients with SLE, Female First-Degree Relatives,
and Unrelated Female Controls
Correlation
Female Patients
with SLE
( )np 216
Female
First-Degree
Relatives
( )np 220
Unrelated
Female Controls
( )np 387
All Three Groups
( )np 823
R P R P R P R P
Long C4 with:
C4A .765 !.0001 .688 .688 .642 !.0001 .695 !.0001
C4B .230 .0007 .028 .028 .135 .0079 .133 .0001
Short C4 with:
C4A .435 !.0001 .285 .285 .301 !.0001 .335 !.0001
C4B .482 !.0001 .380 .380 .442 !.0001 .437 !.0001
haplotypes, C4 protein phenotypes, and the TNFA pro-
moter polymorphism308GrA to patients with SLE. The
most common RCCX haplotype with a C4A deﬁciency,
monomodular S coding for C4B1 in linkage to the TNF2
allele (i.e., S(C4B1)-TNF2), was signiﬁcantly increased in
transmission to the patients with SLE ( ). By con-Pp .004
trast, C4A6-B1 linked to bimodular LS of RCCX and TNF1
allele (i.e., LS(C4A6-B1)-TNF1) was signiﬁcantly decreased
from the expected transmission frequency in the patient
population ( ). These results are consistent withPp .011
results observed in case-control studies suggesting that
C4A deﬁciency is a risk factor for SLE. On the other hand,
RCCXhaplotypes coding for C4A6 appear to be protective.
Gene CNV of Complement C4 in an Independent European
American Patient Population with SLE
To validate the association of low GCN of total C4 and/
or C4A deﬁciency with SLE in European Americans, we
examined gene CNV of C4 in an independent group of
patients with SLE. These patients were recruited from two
sources. The ﬁrst source was from Southern California,
consisting of 99 European American patients (89 females
and 10 males). C4 genotyping experiments were per-
formed by genomic Southern-blot analyses that allowed
elucidation of copy numbers for total C4, C4A, C4B, long
C4 genes, short C4 genes, and the RCCX modules. The
second source was APSCORE, providing 29 female patients
with SLE who were not symptomatic for thrombosis or
recurrent spontaneous abortions. A novel series of real-
time PCR strategies were applied to determine the GCNs
of total C4, C4A, and C4B (Y.L.W., S.L.S., Y.Y., B.Z., B.H.R.,
D.J.B., H.N.N., L.A.H., and C.Y.Y., unpublished data). The
C4 gene CNV results for these patients with SLE were com-
pared with those of unrelated, healthy female controls
from Ohio ( ).np 389
Because of the smaller patient sample size for the rep-
lication study, we categorized the C4 GCN groups into
low, medium, and high. The results showed that 40.6%
of the female replication patients with SLE had low copy
number of total C4 (i.e., two or three copies), which was
similar to the 42.2% of patients in the Ohio SLE study
(tables 4 and 9). The OR for low C4 gene dosage in female
replication patients was 1.67 (95% CI 1.09–2.55; Pp
). The OR for high total C4 gene dosage (i.e., ﬁve, six,.024
or seven copies of total C4) in female replication patients
was 0.52, although the difference from controls was not
statistically signiﬁcant.
The frequency of subjects with homozygous or hetero-
zygous C4A gene deﬁciency (i.e., zero or one copy of the
C4A gene) was 35.6% in the female replication patients
with SLE, which was similar to the 32.5% in Ohio patients
with SLE. The OR for low C4A GCN was 2.12 (95% CI
1.35–3.33; ), and the OR for high C4A GCN wasPp .001
0.39 (95% CI 0.21–0.73; ) in female replicationPp .002
patients. The OR in the Ohio SLE cohort for low C4AGCN
was 2.02 (95% CI 1.38–2.96; ) and, for high C4APp .0003
GCN, was 0.57 (95% CI 0.37–0.89; ) (table 9).Pp .012
The gene-copy indices for total C4 and C4A were 3.68
and 1.75, respectively, in the female replication patients
with SLE. In the Ohio SLE cohort, the corresponding gene-
copy indices were 3.56 and 1.81 (in healthy controls, gene-
copy indices were 3.81 for totalC4 and 2.05 forC4A) (table
5). These results are consistent with the notion that low
total C4 or low C4A GCNs are more prevalent, whereas
high C4A GCN is less frequent in both groups of patients
with SLE.
Discussion
Two recent genome-scan meta-analyses identiﬁed similar
genomic regions—namely, 6p21.1-6p22.3 and 6p21.1-
6q15—that have the most consistent evidence of linkage
with human SLE.6,57 The human MHC (also known as
“HLA”) is implicated as an SLE susceptibility locus in both
studies. Indeed, multiple linkage or association studies
have suggested that HLA haplotypes with DR3, DR2 (i.e.,
DRB1*1501) (HLA-DRB1 [MIM 142857]), or B8 (HLA-B
[MIM 142830]); deﬁciencies of MHC class III gene com-
plement C4A or complement C2; and the promoter poly-
morphism of TNFA (308GrA) are risk factors for
SLE.19,53,58–60 A limitation for most epidemiologic studies
on MHC and associated diseases is that, although poly-
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Table 7. CNV of C4A and the TNFA 5308 GrA Polymorphism in European American
Female Patients with SLE and Controls
Factor
No. (%) of
x2 P
Female
Controls
Female
Patients OR (95% CI)
TNF2 and TNF1
TNF2 allele 58 (17.0) 100 (23.1) 4.501 .039 1.48 (1.03–2.11)
TNF1 allele 284 (83.0) 332 (76.9)
Total 342 (100) 432 (100)
TNF2 carriers 53 (31.2) 87 (40.3) 3.41 .07 1.49 (.98–2.27)
TNF1 only 117 (68.8) 129 (59.7)
Total 170 (100) 216 (100)
C4A GCN: … … 14.5 .0002 2.59 (1.57–4.28)
Low C4A (!2) 27 (15.9) 71 (32.9)
Medium/high C4A (2) 143 (84.1) 145 (67.1)
Total 170 (100) 216 (100)
Controlling for C4A GCN:
Low C4A (!2): … … .95 .366
TNF1 6 (22.2) 10 (14.1)
TNF2 carrier 21 (77.8) 61 (85.9)
Total 27 (100) 71 (100)
Medium C4A (2): … … 0 1.000
TNF1 78 (83.0) 93 (83.0)
TNF2 carrier 16 (17.0) 19 (17.0)
Total 94 (100) 112 (100)
High C4A (12): … … 1.28 .321
TNF1 33 (67.4) 26 (78.8)
TNF2 carrier 16 (32.7) 7 (21.2)
Total 49 (100) 33 (100)
Controlling for TNFA
polymorphism:
TNF2 carrier: … … 16.0 .0003
Low C4A 21 (39.6) 61 (70.1)
Medium C4A 16 (30.2) 19 (21.8)
High C4A 16 (30.2) 7 (8.05)
Total 53 (100) 87 (100)
TNF1 only … … 2.57 .277
Low C4A 6 (5.13) 10 (7.75)
Medium C4A 78 (66.7) 93 (72.1)
High C4A 33 (28.2) 26 (20.2)
morphic variants, SNPs, or microsatellites of MHC iden-
tiﬁed yield consistent results to establish linkage or iden-
tify haplotypes with higher risk of disease susceptibility,
they do not necessarily provide insights on the causative
allele(s). The strong linkage disequilibrium (LD) of MHC
class I, II, and III alleles in many MHC ancestral haplo-
types59,61 imposes great difﬁculty for identifying which
candidate gene or genes are the most relevant in MHC-
associated diseases, including SLE. In addition, there had
been a lack of accurate data on the gene CNVs of com-
plement C4A and C4B in healthy controls and patients
with SLE. There is also no knowledge of microsatellites or
tagging SNPs that can serve as surrogates ofC4 geneCNVs.
The recent advance of the International HapMap Project
has yielded large quantities of information on the SNPs
and LD blocks in human genomes from three racial
groups, including those in the MHC.62,63 This information
will provide a foundation for future deliberate analyses of
causal variants in MHC-associated disease.64 Through a
preliminary analysis of LD blocks of SNPs in the MHC in
European Americans from the centromeric class II DR re-
gion through the central class III region to the telomeric
class I region, it appears that the RCCX modules with
complement C4A and C4B are present in different major
LD blocks from the class II DR region and the TNFA region
close to the class I genes (UCSC Genome Browser).
To date, complete DNA sequences for three HLA con-
sanguineous cell lines corresponding to haplotypesA1-B8-
Cw7-DR3-DQ2 (cell line COX),65 A3-B7-Cw7-DR15-DQ6
(cell line PGF),65 and A26-B18-Cw5-DR3-DQ2 (cell line
QBL)66 have been published (MHC Haplotype Project).
Two regions in the human MHC are conﬁrmed to have
gene CNVs. The ﬁrst CNV region is in the class II region
between DRB1 (a functional gene) and DRB9 (a nonfunc-
tional gene segment) that houses zero or one additional
DRB functional gene (DRB3, DRB4, or DRB5), and zero,
one, or two copies of DRB pseudogenes (DRB2, DRB6,
DRB7, or DRB8). The second CNV region is the RCCX
modular variation at the class III region, as described in
the present article. Similar to our observations of family
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Figure 5. Signiﬁcant increase in the frequency of monomodular S RCCX haplotype with C4A deﬁciency linked to the 308A allele of
the TNFA gene (S-TNF2) in SLE. A, Number and frequency (Freq.) of each haplotype in unrelated female controls (FC), female ﬁrst-degree
relatives (FF), and female patients with SLE (FP). B, Differences between the three groups. NonS-TNF2 p TNF2 allele not linked to
monomodular S haplotype of RCCX; NonS-TNF1 p 308G allele of the TNFA gene not linked to monomodular S haplotype of RCCX.
Table 8. FBAT for RCCX, C4, and TNFA Haplotypes in the Ohio SLE Cohort
Haplotype Frequency
No. of
Families
Observed
Score
Expected
Score P
RCCX:
S and L .209 105 82 68.4 .014
S .127 81 61 47.7 .005
C4:
B1 .129 82 61 48.1 .005
A6B1 .041 31 11 17.1 .03
AQ0X .164 98 75 62.0 .013
TNFA:
TNF2 .191 88 109 118 .078
RCCX(C4)-TNFA:
S(C4B1)-TNF2 .112 58 54 42.5 .004
LS(C4A6B1)-TNF1 .032 25 8.5 14.8 .011
NOTE.—All markers as a group—including RCCX, C4, TNFA, and RCCX(C4)-TNFA but not TNFA—
were statistically signiﬁcant. The individual haplotypes in each marker group were then tested
and are summarized above. AQ0X represents bimodular RCCX structure with a mutant C4A gene
with a 2-bp insertion in exon 29 (C4AQ0) and a functional C4B gene that can code for a C4B1
or C4B2 protein.
C008 published elsewhere,36 the A1-B8-Cw7-DR3-DQ2
haplotype has DRB2 (pseudogene) and DRB3 (functional
gene) between DRB1 and DRB9 in the class II region and
monomodular S RCCX with a single short C4B gene in
the class III region; the A3-B7-Cw7-DR15-DQ6 haplotype
has DRB5 and DRB6 (pseudogene) between DRB1 and
DRB9 in the class II region and a bimodular long-long (LL)
RCCX haplotype coding for C4B1-A3 in the class III re-
gion.36 Intriguingly, the order of C4A and C4B genes with
respect to C2/factor B and DR are reversed (i.e., C4B-C4A
instead of C4A-C4B) in this B7-DR15 haplotype.65 For the
A26-B18-Cw5-DR3-DQ2 haplotype, DRB2 and DRB3 are
present in the class II region, and the monomodular L
with a single C4A gene is present in the class III region.
The presence of three different RCCX/C4 GCN and length
variants in three HLA haplotypes underscores the struc-
tural complexity of complement C4A and C4B.
In the present study, we establish strong correlations of
gene CNV of complement C4 (total C4) and its associated
polymorphisms (C4A and longC4 genes) with humanSLE.
Typical of many susceptibility genes associated with an
autoimmune disease, the risk factor (i.e., low copynumber
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Table 9. Replication Study to Validate Low
GCN of Total C4 or C4A as Risk Factor for
and High GCN as Protective Factor against
SLE in European Americans
Gene, Patients,
and GCN OR (95% CI) Pa
Total C4:
Ohiob:
2 or 3 1.823 (1.287–2.583) .001
4 .737 (.527–1.030) .087
5 or 6 .466 (.246–.882) .016
SPc:
2 or 3 1.666 (1.087–2.554) .024
4 .783 (.518–1.184) .289
5 or 6 .520 (.239–1.132) .129
C4A:
Ohiob:
0 or 1 2.024 (1.384–2.959) .0003
2 .825 (.590–1.153) .268
3, 4, or 5 .574 (.370–.890) .012
SPc:
0 or 1 2.121 (1.352–3.326) .001
2 .926 (.612–1.400) .752
3, 4, or 5 .391 (.210–.729) .002
a P value calculated by Fisher’s exact test.
b Prospective European American patients with SLE
who are from Ohio.
c Independent European American patients with
SLE who were part of a replication study.
of total C4 or C4A) is present in the general population,
but the prevalence is signiﬁcantly increased in the patient
population (with SLE). Importantly, a dose-dependent
phenomenon from increased SLE disease risk at low GCN
to protection against disease susceptibility at high GCN is
observed for both total C4 and C4A. The RCCX modular
variation reﬂects differences in the copy number and con-
ﬁgurations of long and short C4A or C4B genes in a hap-
lotype. This study shows that monomodular RCCX struc-
ture with a short C4B gene and the absence of C4A is a
relatively common haplotype among European American
patients with SLE. By contrast, trimodular RCCX haplo-
types with three functional C4 genes are less frequent
among patients with SLE.
We employ the concept of gene-copy index (i.e., the
mean copy number of a speciﬁc gene in a selected pop-
ulation) to facilitate a quantitative comparison of gene
CNV among groups. The results provide a quantitative
basis for gene CNV of total C4 or C4A as a risk factor for
or a protective factor against SLE disease susceptibility.The
gene-copy indices of total C4 and C4A in the female ﬁrst-
degree relatives are lower than those in unrelated healthy
controls but are higher than those in patients with SLE.
This suggests that ﬁrst-degree relatives of patientswith SLE
are harboring some genetic risk factor for autoimmune
disease, but most of them are healthy probably because
of the weak penetrance of genetic risk factors involved in
complex diseases and/or because their milieus of genetic
and environmental risk factors have not reached the
threshold to initiate the disease process. Nevertheless, the
lower total C4 and C4A GCNs in ﬁrst-degree relatives than
in unrelated healthy controls would offer a logical expla-
nation for the higher incidence and clustering of auto-
immune diseases in family members of patients with
SLE.1,4 A replication study involving an independent pa-
tient cohort reafﬁrmed the role of low total C4 and C4A
GCNs in increased risk of SLE susceptibility.
Besides the SLE disease activities, our data also revealed
that gene CNV of C4 is the predominant genetic factor
that mediates the plasma or serum C4 protein concentra-
tions23,43 (Y.Y., Y.L.W., H.N.N., B.H.R., D.J.B., L.A.H., and
C.Y.Y., unpublished data). Therefore, a comprehensive elu-
cidation of the C4 gene CNV and quantitative variations
of plasma or serum C4 protein levels plus their activation
and/or inactivation split products (C4a and/or C4d)would
yield highly relevant information to help diagnose and
manage SLE.21,23,67,68
Historically, interindividual gene CNV has not been
considered to be a source of inherent genetic diversity.
However, recent advances in global genomewide analysis
have revealed multiple and variable segmental duplica-
tions of genomic regions among different individu-
als.69–71 A public database on human genome diversity lists
3,463 possible loci, including complement C4, that can
have CNV (Human Genome build 35, Database of Ge-
nomic Variants). The data source was mainly derived from
varying ﬂuorescence intensities on microarray chips after
comparative hybridization with labeled genomic DNA
from different human subjects. More-reﬁned studies will
be necessary to elucidate the distribution patterns of in-
terindividual and interpopulation gene CNVs, their re-
lated polymorphisms, and possible physiologic roles in
health and disease.72–74 This is because, although dupli-
cated genomic segments involved in CNVs are highly
homologous, they may not be totally identical in DNA
sequences. Case-by-case examination often reveals sec-
ondary genetic events that yield new markers or poly-
morphisms and sometimes add novel functions to existing
gene products. Although sequence exchanges among var-
iants of duplicated sequences promote diversity, they can
also carry a genetic burden by harboring deleterious mu-
tations. Of the RCCX modules, multiple mutations ac-
cumulated in the CYP21A can be transferred to CYP21B,
which can become allelic when a monomodular RCCX
pairs with a bimodular RCCX and thus abolishes or di-
minishes the enzymatic activity of the steroid 21-hydrox-
ylase. Mutations or the absence of CYP21B are the main
cause of congenital adrenal hyperplasia.34,35,75 Moreover,
the acquisition of the 120-bp deletion from the TNXA
gene fragment by the intact tenascin-X gene TNXB is re-
sponsible for a form of Ehlers-Danlo syndrome (MIM
130020).76
For complement C4, secondary genetic diversiﬁcations
led to the emergence of two forms of C4 genes (long and
short) and two isotypes of C4 proteins (C4A and C4B).
C4A is probably a newly evolved protein that acquires a
novel function by binding effectively to amino groups of
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protein substrates or immune complexes, thereby en-
hancing immune-complex clearance thatwouldotherwise
promote autoimmunity. Gene CNV permits the coexis-
tence and quantitative variation of C4A and C4B proteins
and the emergence of new protein variants or allotypes
in each group. C4A6 is a variant allotype that dissociates
the lytic pathway from the classical or lectin activation
pathway of the complement system, as the R458W poly-
morphism in C4A6 disables the binding of C5 and ab-
rogates the C5 convertase activity of C4b2a3b.77,78 This
study suggests that C4A6 could be a protective factor
against SLE. One possibility is that this allotype could
attenuate the deleterious effects of complement lytic
pathway–mediated tissue injury during an autoimmune
process.
In addition to C4A deﬁciency, we have also examined
two other genetic risk factors in MHC class III region—
namely, the deﬁciency of complement C279,80 and the
308A allele of TNFA (i.e., the TNF2 allele)—as suscepti-
bility factors for SLE.81–83 Complement C2 deﬁciency ap-
peared infrequently in our patients with SLE, since only
one homozygous and four heterozygous C2 deﬁciencies
were present among 233 Ohio patients with SLE. On the
other hand, a signiﬁcant increase in the frequency ofTNF2
in SLE was observed (patients 0.231; controls 0.170;
; ). In healthy subjects, close to half ofORp 1.48 Pp .039
the TNF2 alleles are linked to monomodular S of RCCX,
S-TNF2. In SLE, the increase of TNF2 frequency appeared
to be secondary to the increase of monomodular S with
C4A deﬁciency, which had a haplotype frequency of 0.164
in patients with SLE and 0.079 in unrelated healthy con-
trols. By contrast, the frequency of TNF2 alleles not as-
sociated with monomodular S (i.e., nonS-TNF2) was re-
duced in patients with SLE (patients 0.067; controls
0.091). The relevance of the S-TNF2 haplotype in SLE was
further substantiated by FBAT analysis.
The strength of this work lies on the high resolution
and the comprehensiveness by which the diversities of
C4A and C4B genotypes and phenotypes in healthy sub-
jects and in patients with SLE are elucidated. Recently,
association between gene CNV and human disease has
been documented in three other incidences: an increased
risk of HIV infection and progression to severe disease for
individuals with low GCN of CCL3L1,84 low copy number
of beta-defensin 2 in inﬂammatory bowel disease,85 and
possibly low GCN of immunoglobulin receptor FCGR3B
in glomerulonephritis.86 Further detailed analysis of gene
CNV and associated genetic diversities in human popu-
lations promises to increase our understanding of complex
diseases and quantitative genetic traits.87,88
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